Searched over 200M research papers for "stopping lisinopril"
7 papers analyzed
These studies suggest stopping lisinopril may negatively impact prognosis after myocardial infarction, blood pressure control in children, and long-term management of hypertension and heart failure.
20 papers analyzed
Lisinopril is an angiotensin-converting enzyme (ACE) inhibitor commonly prescribed for conditions such as hypertension, heart failure, and acute myocardial infarction (MI). It works by relaxing blood vessels, making it easier for the heart to pump blood. However, the implications of stopping lisinopril, especially after a period of treatment, are crucial for patient outcomes.
Research from the GISSI-3 trial provides significant insights into the effects of stopping lisinopril after acute myocardial infarction. In this study, patients were treated with lisinopril for six weeks and then followed up for six months after stopping the medication. The results indicated that early treatment with lisinopril improved prognosis, with a lower combined endpoint of mortality and severe left ventricular dysfunction observed at six months compared to those who did not receive lisinopril . This suggests that the benefits of lisinopril may persist even after the treatment is discontinued.
A subgroup analysis of diabetic patients in the GISSI-3 study showed that early treatment with lisinopril significantly reduced six-week mortality rates. This benefit was largely maintained at six months, even after stopping the medication at six weeks. This highlights the importance of early intervention with lisinopril in high-risk populations, such as diabetic patients, to improve long-term outcomes.
Lisinopril has been shown to be generally well-tolerated in both hypertensive and heart failure patients. Common side effects include headache, dizziness, cough, and nausea, with a small percentage of patients discontinuing due to adverse events. The safety profile of lisinopril supports its use, but careful monitoring is necessary, especially when discontinuing the medication to avoid potential rebound effects.
A study on hypertensive children demonstrated a clear dose-response relationship with lisinopril, where higher doses resulted in more significant blood pressure reductions. Upon withdrawal, blood pressure increased, indicating the necessity of continued treatment for sustained blood pressure control. This finding underscores the importance of managing the cessation of lisinopril carefully to prevent adverse outcomes.
Lisinopril has been shown to reduce left ventricular dilatation after myocardial infarction, which is a predictor of poor prognosis. The GISSI-3 trial found that short-term treatment with lisinopril attenuated left ventricular dilatation, an effect that persisted even after the medication was stopped. This suggests that early intervention with lisinopril can have lasting benefits on cardiac structure and function.
Stopping lisinopril after a period of treatment, particularly following acute myocardial infarction, can still result in sustained benefits, such as reduced mortality and improved left ventricular function. However, careful consideration and monitoring are essential to manage potential rebound effects and ensure continued patient safety. The evidence supports the early use of lisinopril in high-risk patients, such as those with diabetes, to maximize long-term outcomes.
Most relevant research papers on this topic